Jan 09, 2017
AbbVie, a global biopharmaceutical company, has announced four new collaborations and investments with leading healthcare innovators for advancing early-stage research in key therapeutic areas such as immunology and oncology. The company is committed to investing in and developing transformational science and technologies to advance the next-generation of therapies across its robust pipeline in key therapeutic areas.
AbbVie and Pure MHC, a privately-held target discovery company, will focus on a research and license agreement for discovering and validating peptide targets for use with T-cell receptor therapeutics in several types of cancers. The collaboration between AbbVie and Pure MHC will seek to find out a library of peptide targets to further research across multiple tumor types and advance the ongoing development of next-generation immuno-oncology therapies by AbbVie.
AbbVie has also entered into an exclusive license with Dong-A-ST, a leading specialty healthcare company in South Korea, for MerTK inhibitors in pre-clinical development for use in conjunction with immuno-oncology therapies. This collaboration will explore the combination of AbbVie’s portfolio of anti-cancer agents in conjunction with MerTK inhibitors across multiple types of solid tumors.
Furthermore, AbbVie and Zebra Biologics, Inc., a discovery stage biotechnology company, have entered into a partnership to discover agonist antibody therapeutics for inflammatory diseases. Zebra will utilize its novel and patented function-based antibody discovery platform to generate antibodies that activate biological pathways associated with targets designated by AbbVie.
Finally, AbbVie and Genomics Medicine Ireland (GMI), a life sciences startup company, have partnered to conduct population genomics research in Ireland. This alliance will sequence the genomes of 45,000 volunteers across Ireland. The data to be included will originate from people with several types of immune-mediated diseases, neurological disorders and cancer, as well as people unaffected by these diseases. The target is to better understand human biology and disease etiology by discovering new therapeutic targets and identify biomarkers.
Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie, said: “We can develop tomorrow’s most important therapies by investing in today’s leading technologies and scientific achievements. Combining the strengths of AbbVie’s discovery and development expertise and novel research from external partners will accelerate the pace of innovation into new medicines for the next-generation of medical treatment.”